Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in BRAFV600 Melanoma: Current Status and Future Perspectives

SIMPLE SUMMARY: With the development of immunotherapies and targeted therapies in the last years, there has been great progress in the outcome of patients with metastatic melanoma. One of the current challenges is to optimize the treatment efficacy, to overcome resistance and to prevent disease rela...

Descripción completa

Detalles Bibliográficos
Autores principales: Welti, Michèle, Dimitriou, Florentia, Gutzmer, Ralf, Dummer, Reinhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688939/
https://www.ncbi.nlm.nih.gov/pubmed/36428582
http://dx.doi.org/10.3390/cancers14225489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688939/
https://www.ncbi.nlm.nih.gov/pubmed/36428582
http://dx.doi.org/10.3390/cancers14225489

Ejemplares similares